Abstract:Lung cancer is a lethal disease, and early diagnosis with the aid of biomarkers such as HSP90α protein can certainly assist the doctors to start treatment of patient at the earliest and can save their lives. To analyse the diagnostic value of HSP90α expression in lung cancer patients by collecting data of patients through IoT devices to avoid delay in treatments, a study has been presented in this paper where the significance of HSP90α biomarker is highlighted in early diagnosis of patients suffering from lung cancer. The second objective of the research study is to examine the correlation between the appearance level of HSP90α biomarker and the clinicopathological features of lung cancer. It is also evaluated whether the changes in HSP90α index are indicative or noteworthy before and after surgery of lung cancer patients. An observatory study of 78 patients with lung cancer in Qinhuangdao Hospital is presented in this paper where the samples were collected from June 2018 to March 2020. Their data were collected through IoT devices used in the latest healthcare facilities of the hospital. The ELISA method was utilized to identify the level of plasma HSP90 and to analyse HSP90 levels between the lung cancer group and healthy group of people. The relationship between HSP90 and the clinical pathological features of 78 patients suffering from lung cancer was analysed. An electrochemical luminescence method was used to detect CEA, NSE, SCC, and CYFRA21-1 levels. ROC curve and box plots were used to determine the analytic value of HSP90 and other biomarkers used in lung cancer diagnosis. Forty-two patients with moderate to early stage lung cancer with surgical correction were selected, and paired sample T test was used to analyse HSP90 levels before and after surgery. The plasma HSP90 level of lung cancer patients was quite higher as compared to the group of healthy people as per the values depicted in the research study. Second, HSP90 levels are substantially higher in pathologic type, differentiation degree, stage, and the existence of the lung, liver, and bone metastases (P < 0.05). The level of HSP90 expression was largely impacted by a few factors such as sex, age, smoking, and tumour location (P > 0.05). The ROC value for HSP90 was 0.599, while the area under the curve of HSP90 combined with other four tumour markers was 0.915 in the presented case study, indicating the presence of lung cancer. Patients with lung cancer had statistically significant differences in HSP90 expression levels before and after surgery (P < 0.05). It is concluded that the expression level of plasma HSP90α in lung cancer patients increases remarkably; therefore, HSP90 can be used to monitor presence of lung cancer before and after surgery in the patients.

Plasma heat shock protein 90 alpha in the diagnosis and treatment of breast cancer

Plasma Levels of Heat Shock Protein 90 Alpha Associated with Lung Cancer Development and Treatment Responses.

Plasma Levels of Heat Shock Protein 90 Alpha Associated With Colorectal Cancer Development

Extracellular Hsp90 Promotes Tumor Lymphangiogenesis and Lymph Node Metastasis in Breast Cancer

Plasma Heat Shock Protein 90alpha As a Biomarker for the Diagnosis of Liver Cancer: an Official, Large-scale, and Multicenter Clinical Trial.

A Novel Pan‐cancer Biomarker Plasma Heat Shock Protein 90alpha and Its Diagnosis Determinants in Clinic

Diagnostic value of plasma HSP90α levels for detection of hepatocellular carcinoma

Diagnostic value of HSP90α and Related Markers in Lung Cancer

Plasma HSP90AA1 Predicts the Risk of Breast Cancer Onset and Distant Metastasis

Expression of Hsp90α in blood of patients with lung cancer

Heat Shock Protein 90α Provides an Effective and Novel Diagnosis Strategy for Nasopharyngeal Carcinoma

Integrative Analysis of Plasma Metabolomics and Proteomics Reveals the Metabolic Landscape of Breast Cancer

Heat-shock protein 90α is a potential prognostic and predictive biomarker in hepatocellular carcinoma: a large-scale and multicenter study

Clinicopathologic significance of heat shock protein 60 as a survival predictor in breast carcinoma

Expression of heat shock protein 27, 60 and 90 in gastric cancer and its clinical value

The circulating 70 kDa heat shock protein (HSPA1A) level is a potential biomarker for breast carcinoma and its progression

Clinical significance of heat shock protein 90α expression as a biomarker of prognosis in patients with gastric cancer

Circulating Heat Shock Protein 70 Is a Novel Biomarker for Early Diagnosis of Lung Cancer

Impact of HSP90 α, CEA, NSE, SCC, and CYFRA21-1 on Lung Cancer Patients

Prognostic Impact of Heat Shock Protein 90 Expression in Women Diagnosed with Cervical Cancer

Identification of HSP90B1 in pan-cancer hallmarks to aid development of a potential therapeutic target